At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 201 enrolled
Drug / intervention
Oral Risperidone +1 moredrug
Likely dose
Oral Risperidone 6 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Blinded-initiation Study of Medication Satisfaction in Subjects With Schizophrenia Treated With Paliperidone ER After Suboptimal Response to Oral Risperidone
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·interventional·Posted Sep 26, 2007·Updated May 9, 2014
In Brief
A Phase 4 clinical trial evaluating Oral Risperidone and Paliperidone ER for Schizophrenia. Completed, enrolled 201 participants across 40 sites in 6 countries.
Detailed Summary
The purpose of this study is to evaluate medication satisfaction after at least 4 weeks of paliperidone ER (extended-release), an antipsychotic, treatment in patients with schizophrenia who were previously taking either 4 or 6 mg of risperidone daily by mouth, but who are not satisfied with their treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesArgentina, Colombia, Czechia, Slovakia, Ukraine, United States
Collaborators--
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 2007
Enrollment StartOct 2007
Primary CompletionJul 2008
TodayJul 2026
First PostedSep 26, 2007
Enrollment StartOct 1, 2007
Primary CompletionJul 1, 2008
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 18.8 years ago
Interventions
Oral Risperidonedrug
4 or 6 mg MG once daily for 0-2 weeks
Paliperidone ERdrug
6, 9 or 12 MG once daily for 4-6 weeks